INTUNIV: payments to doctors
Payments that named INTUNIV as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Shire North American Group Inc?
Shire North American Group Inc reported the most payments naming INTUNIV. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $53K
- Providers
- 3
- Transactions
- 45
- Average per transaction
- $1,174
The per-transaction average — $1,174 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3 providers the average total is $17,617, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Shire North American Group Inc | $46,115 | 87.3% |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,737 | 12.7% |
Other products from Shire North American Group Inc
The company that reported the most payments naming INTUNIV also reports against these.